Craig L. Tendler, MD, Vice President, Late Development and Global Medical Affairs for Oncology, Janssen Oncology, discusses the importance of ibrutinib's Breakthrough Therapy Designation.
Craig L. Tendler, MD
Advertisement
Articles by Craig L. Tendler, MD
Advertisement
Latest Updated Articles
Dr. Tendler on Breakthrough Designation for IbrutinibPublished: June 26th 2013 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
4
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
5